These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25145426)

  • 1. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial.
    Liguigli W; Tomasello G; Toppo L; Ratti M; Passalacqua R
    Future Oncol; 2014; 10(9):1549-57. PubMed ID: 25145426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
    Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
    Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
    Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
    Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
    Hofheinz RD; Lorenzen S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab: A Review in Advanced Gastric Cancer.
    Greig SL; Keating GM
    BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
    Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
    Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 11. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.
    Tabernero J; Ohtsu A; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Ajani JA; Tomasek J; Safran H; Chandrawansa K; Hsu Y; Heathman M; Khan A; Ni L; Melemed AS; Gao L; Ferry D; Fuchs CS
    Mol Cancer Ther; 2017 Oct; 16(10):2215-2222. PubMed ID: 28716815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
    Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
    J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ramucirumab - a new anticancer agent].
    Telekes A; Deme D
    Orv Hetil; 2016 Oct; 157(40):1587-1594. PubMed ID: 27690622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab: first global approval.
    Poole RM; Vaidya A
    Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of ramucirumab in gastroesophageal adenocarcinoma.
    Elimova E; Lin Q; Song S; Ajani JA
    Future Oncol; 2017 Aug; 13(18):1585-1592. PubMed ID: 28436242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Kim TY; Yen CJ; Al-Batran SE; Ferry D; Gao L; Hsu Y; Cheng R; Orlando M; Ohtsu A
    Gastric Cancer; 2018 Mar; 21(2):276-284. PubMed ID: 28634748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
    Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
    Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab approved for gastric cancer.
    Cancer Discov; 2014 Jul; 4(7):752-3. PubMed ID: 25002597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.